LJN452

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Non-alcoholic Fatty Liver DiseasePrimary Bile Acid Diarrhea

Phase 1

Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects

CompletedNCT03681457

Novartis PharmaceuticalsNon-alcoholic Fatty Liver Disease

Start: 2018-09-24End: 2019-09-25Updated: 2020-12-14

Phase 2

To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.

CompletedNCT02713243

Novartis PharmaceuticalsPrimary Bile Acid Diarrhea

Start: 2016-01-16End: 2018-01-25Updated: 2021-01-05

Related Papers

Randomised clinical trial: significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea

Alimentary Pharmacology & Therapeutics2020-07-2345 citations